Proton pump inhibitors receiving and prognosis of patients after scheduled percutaneous coronary interventions.

Journal: Terapevticheskii arkhiv

PMID: 30701742

Abstract

AIM: The urgency of the study is determined by the lack of data necessary in order to assess the safety of prolonged use of proton pump inhibitors (PPI) in patients with IHD combined with anti-aggregant therapy. The aim of the study was to study the relationship between the use of PPI and the risk of thrombotic complications in patients undergoing planned procedures of percutaneous coronary interventions (PCI) and receiving dual antiplatelet therapy.

Authors

A L Komarov

Department of Clinical Problems of Atherothrombosis of the National Medical Research Center for Cardiology, Moscow, Russia.
O O Shakhmatova

Department of Clinical Problems of Atherothrombosis of the National Medical Research Center for Cardiology, Moscow, Russia.
V G Muraseeva

Department of Clinical Problems of Atherothrombosis of the National Medical Research Center for Cardiology, Moscow, Russia.
E S Novikova

Department of Clinical Problems of Atherothrombosis of the National Medical Research Center for Cardiology, Moscow, Russia.
E V Guskova

Pirogov National Medical and Surgical Center, Moscow, Russia.
E P Panchenko

Department of Clinical Problems of Atherothrombosis of the National Medical Research Center for Cardiology, Moscow, Russia.

Keywords

Acute Coronary Syndrome Aged Coronary Restenosis Drug Therapy, Combination Female Gastrointestinal Hemorrhage Humans Long Term Adverse Effects Male Middle Aged Myocardial Ischemia Percutaneous Coronary Intervention Platelet Aggregation Inhibitors Prognosis Prospective Studies Proton Pump Inhibitors Registries Risk Adjustment Russia

External Resources

View on PubMed Access via DOI PubMed (30701742)

Proton pump inhibitors receiving and prognosis of patients after scheduled percutaneous coronary interventions.

Abstract

Authors

Keywords

External Resources

Popular Topics

Recent Journals